




Searching News Database: rheumatoid arthritis
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
HSMN NewsFeed - 20 Apr 2021
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
HSMN NewsFeed - 10 Aug 2020
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
HSMN NewsFeed - 4 Jun 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
Mylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
HSMN NewsFeed - 2 Dec 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
HSMN NewsFeed - 10 Oct 2019
FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
HSMN NewsFeed - 14 May 2019
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
HSMN NewsFeed - 28 Nov 2018
Generex Biotechnology Expands Medical Device Portfolio With Acquisition of Olaregen Therapeutix Inc.
Generex Biotechnology Expands Medical Device Portfolio With Acquisition of Olaregen Therapeutix Inc.
HSMN NewsFeed - 28 Jun 2018
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
HSMN NewsFeed - 7 Mar 2018
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
HSMN NewsFeed - 8 May 2017
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
HSMN NewsFeed - 9 Feb 2017
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process
HSMN NewsFeed - 4 Jan 2017
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
Regeneron Hires Jay Markowitz, M.D., as Senior Vice President of Portfolio Management
HSMN NewsFeed - 16 Nov 2016
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products
Cumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group's Methotrexate Injection Products
HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
HSMN NewsFeed - 31 Oct 2016
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 12 Sep 2016
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
HSMN NewsFeed - 16 Jan 2016
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
HSMN NewsFeed - 13 Jan 2016
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
HSMN NewsFeed - 3 Dec 2015
Mundipharma Establishes an Ophthalmology Business by Acquiring MSD's Portfolio of Glaucoma Products
Mundipharma Establishes an Ophthalmology Business by Acquiring MSD's Portfolio of Glaucoma Products
HSMN NewsFeed - 10 Aug 2015
Chiasma Expands Management Team with Announcement of Anand Varadan as Chief Commercial Officer
Chiasma Expands Management Team with Announcement of Anand Varadan as Chief Commercial Officer
HSMN NewsFeed - 26 Jun 2015
EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
EYLEA(R) (aflibercept) Injection Receives Approval in Japan for the Treatment of Retinal Vein Occlusion
HSMN NewsFeed - 1 Jun 2015
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
HSMN NewsFeed - 18 Nov 2014
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
HSMN NewsFeed - 15 Sep 2014
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer
HSMN NewsFeed - 11 Aug 2014
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
HSMN NewsFeed - 30 Dec 2013
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
HSMN NewsFeed - 19 Nov 2013
Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical Development
Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical Development
HSMN NewsFeed - 19 Nov 2013
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
Horizon Pharma Announces Agreement to Acquire U.S. Rights to VIMOVO(R) and Provides 2014 Guidance
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 3 Oct 2013
Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
HSMN NewsFeed - 22 Aug 2013
Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
HSMN NewsFeed - 11 Apr 2013
BD Announces FDA 510(k) Clearance and Commercial Launch of BD UltraSafe PLUS(TM) Passive Needle Guard
BD Announces FDA 510(k) Clearance and Commercial Launch of BD UltraSafe PLUS(TM) Passive Needle Guard
HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
HSMN NewsFeed - 17 Dec 2012
Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA
Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA
HSMN NewsFeed - 13 Nov 2012
Antares Pharma Announces Positive Results from Final MTX Medi-Jet(TM) Clinical Study
Antares Pharma Announces Positive Results from Final MTX Medi-Jet(TM) Clinical Study
HSMN NewsFeed - 16 Oct 2012
BioAdvance Expands Team to Support Portfolio Companies and New Investments
BioAdvance Expands Team to Support Portfolio Companies and New Investments
HSMN NewsFeed - 12 Oct 2012
Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer
Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer
HSMN NewsFeed - 4 Sep 2012
Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
HSMN NewsFeed - 19 Jun 2012
AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
AstraZeneca And Rigel Sign Worldwide License Agreement For A Potential New Treatment For Chronic Asthma
HSMN NewsFeed - 3 May 2012
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection
HSMN NewsFeed - 25 Apr 2012
Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
HSMN NewsFeed - 7 Feb 2012
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
HSMN NewsFeed - 20 Jan 2012
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
HSMN NewsFeed - 6 Dec 2011
Amgen and FDA Agree to Modify Nplate(R) (Romiplostim) Risk Evaluation and Mitigation Strategy
Amgen and FDA Agree to Modify Nplate(R) (Romiplostim) Risk Evaluation and Mitigation Strategy
HSMN NewsFeed - 8 Nov 2011
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
Abbott Reports Five-Year Data for HUMIRA(R) (Adalimumab) in Ankylosing Spondylitis
HSMN NewsFeed - 10 Oct 2011
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
HSMN NewsFeed - 4 Aug 2011
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
HSMN NewsFeed - 7 Jun 2011
XOMA Appoints Paul Rubin, M.D. as Vice President and Chief Medical Officer
XOMA Appoints Paul Rubin, M.D. as Vice President and Chief Medical Officer
HSMN NewsFeed - 20 May 2011
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
HSMN NewsFeed - 15 Apr 2011
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
HSMN NewsFeed - 24 Mar 2011
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
HSMN NewsFeed - 23 Mar 2011
Blue Cross and Blue Shield Companies to Reimburse SBi’s STAR(TM) Total Ankle Replacement
Blue Cross and Blue Shield Companies to Reimburse SBi’s STAR(TM) Total Ankle Replacement
HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
HSMN NewsFeed - 23 Feb 2011
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
HSMN NewsFeed - 9 Feb 2011
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
HSMN NewsFeed - 21 Dec 2010
Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
HSMN NewsFeed - 14 Oct 2010
Catabasis Pharmaceuticals Appoints Michael Curtis, Ph.D., as Vice President, Product Development
Catabasis Pharmaceuticals Appoints Michael Curtis, Ph.D., as Vice President, Product Development
HSMN NewsFeed - 7 Oct 2010
Integra LifeSciences Features the Integra(TM) Total Wrist Fusion System at the 65th Annual ASSH Meeting
Integra LifeSciences Features the Integra(TM) Total Wrist Fusion System at the 65th Annual ASSH Meeting
HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
HSMN NewsFeed - 15 Jul 2010
Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer
Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer
HSMN NewsFeed - 28 May 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
HSMN NewsFeed - 3 May 2010
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
HSMN NewsFeed - 19 Feb 2010
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
HSMN NewsFeed - 7 Jan 2010
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
HSMN NewsFeed - 4 Jan 2010
Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
HSMN NewsFeed - 10 Nov 2009
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
HSMN NewsFeed - 5 Nov 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 14 Oct 2009
XOMA Appoints Susan Kramer, Dr. P.H. Vice President of Project and Alliance Management
XOMA Appoints Susan Kramer, Dr. P.H. Vice President of Project and Alliance Management
HSMN NewsFeed - 5 Oct 2009
Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
HSMN NewsFeed - 14 Sep 2009
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
POZEN Names Elizabeth A. Cermak as Executive Vice President, Chief Commercial Officer
HSMN NewsFeed - 15 Jun 2009
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
HSMN NewsFeed - 19 May 2009
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
HSMN NewsFeed - 20 Apr 2009
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
HSMN NewsFeed - 15 Apr 2009
Resolvyx Appoints Industry Leader Philip Vickers as Chief Scientific Officer
Resolvyx Appoints Industry Leader Philip Vickers as Chief Scientific Officer
HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed - 27 Feb 2009
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
HSMN NewsFeed - 29 Jan 2009
POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint
POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence Continues to Be an Acceptable Primary Endpoint
HSMN NewsFeed - 19 Jan 2009
IBT Labs Adds Senior R&D, Marketing, and Sales Executives to Leadership Team
IBT Labs Adds Senior R&D, Marketing, and Sales Executives to Leadership Team
HSMN NewsFeed - 22 Dec 2008
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
HSMN NewsFeed - 10 Dec 2008
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
HSMN NewsFeed - 4 Dec 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
HSMN NewsFeed - 26 Nov 2008
MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease
MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease
HSMN NewsFeed - 8 Oct 2008
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
HSMN NewsFeed - 18 Sep 2008
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life
HSMN NewsFeed - 15 Sep 2008
Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen
Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen
HSMN NewsFeed - 10 Sep 2008
Cytomedix Appoints Dr. Peter A. Clausen as Vice President of Business Development
Cytomedix Appoints Dr. Peter A. Clausen as Vice President of Business Development
HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 3 Sep 2008
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
HSMN NewsFeed - 3 Sep 2008
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
HSMN NewsFeed - 28 Jul 2008
AVI BioPharma Appoints New Senior Vice President and Chief Financial Officer
AVI BioPharma Appoints New Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 25 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
HSMN NewsFeed - 24 Jun 2008
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Chronic Plaque Psoriasis
HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
HSMN NewsFeed - 18 Jun 2008
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 31 May 2008
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
HSMN NewsFeed - 15 May 2008
CDC Recommends ZOSTAVAX(R), Merck's Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
CDC Recommends ZOSTAVAX(R), Merck's Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
HSMN NewsFeed - 24 Apr 2008
Transdel Pharmaceuticals Appoints Chief Medical Officer and Chief Operating Officer
Transdel Pharmaceuticals Appoints Chief Medical Officer and Chief Operating Officer
HSMN NewsFeed - 22 Apr 2008
Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders
Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders
HSMN NewsFeed - 17 Apr 2008
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
HSMN NewsFeed - 16 Apr 2008
Chemokine Therapeutics Announces New President And Chief Executive Officer
Chemokine Therapeutics Announces New President And Chief Executive Officer
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 8 Apr 2008
Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
HSMN NewsFeed - 20 Mar 2008
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
HSMN NewsFeed - 7 Mar 2008
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
HSMN NewsFeed - 5 Mar 2008
Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody
Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody
HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
HSMN NewsFeed - 6 Feb 2008
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
HSMN NewsFeed - 4 Feb 2008
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
HSMN NewsFeed - 29 Jan 2008
KaloBios Strengthens Development Expertise With Additions to Senior Management Team
KaloBios Strengthens Development Expertise With Additions to Senior Management Team
HSMN NewsFeed - 23 Jan 2008
Robert A. Scott, M.D., Appointed Chief Medical Officer of Cerenis Therapeutics
Robert A. Scott, M.D., Appointed Chief Medical Officer of Cerenis Therapeutics
HSMN NewsFeed - 18 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
HSMN NewsFeed - 15 Jan 2008
POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
POZEN Submits Human Lymphocyte Study for Treximet(TM) (Formerly Known as Trexima(TM))
HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Additional items found! 500

Members Archive contains
500 additional stories matching:
rheumatoid arthritis
(Password required)
rheumatoid arthritis
(Password required)